Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.GCTK · Entity 8422 | Director | March 25, 2025 | October 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date March 25, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 4,692 |
Ending reported balance
After 2025-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-25 · Grant · Acquired 75 · Balance 75 Row 2 · 2025-07-11 · Grant · Acquired 3,332 · Balance 3,407 Row 3 · 2025-10-03 · Grant · Acquired 1,285 · Balance 4,692 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2035-10-03 | Direct | 4,055 |
Reported balance
After 2025-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-03 · Grant · Acquired 4,055 · Balance 4,055 F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DEXCOM INC
Report date March 10, 2023 · Filed March 14, 2023
Section 16 reporting ended · disclosed 2023-03-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,908 |
Last balance in matching sequence
After 2023-03-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,275 · Balance 59,303 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 2 · 2023-03-10 · Disposition to issuer · Disposed 2,405 · Balance 56,898 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 3 · 2023-03-10 · Disposition to issuer · Disposed 5,990 · Balance 50,908 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 30,212 |
Reported balance
Holding disclosure · report date 2023-03-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,212 F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 205 | $363.46 | $74,510.16 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,217 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $363.23 to $363.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 776 | $362.72 | $281,468.70 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,422 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $362.18 to $363.145. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $361.45 | $72,290.00 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,198 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $360.98 to $361.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $359.98 | $179,990.50 |
DisclosureSEC source: 0001093557-20-000193 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,398 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $359.485 to $360.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 51 | $287.75 | $14,675.25 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 6 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,898 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 730 | $286.24 | $208,956.00 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 5 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,949 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $285.88 to $286.85. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,385 | $285.14 | $680,064.86 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,679 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $284.77 to $285.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,110 | $284.19 | $315,455.90 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,064 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $283.73 to $284.70. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,382 | $281.10 | $388,476.88 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,174 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $280.88 to $281.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,032 | $279.33 | $288,265.77 |
DisclosureSEC source: 0001093557-20-000129 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,556 F1 · shares: On December 11, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $278.90 to $279.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,840 | $265.43 | $2,080,939.84 |
DisclosureSEC source: 0001093557-20-000106 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,588 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 319 | $250.15 | $79,799.22 |
DisclosureSEC source: 0001093557-20-000106 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,428 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $250.028 to $250.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2 | $246.18 | $492.37 |
DisclosureSEC source: 0001093557-20-000106 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,747 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.05 to $246.3187. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 10, 2020 23:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 8,811 | $0.00 | $8.81 |
DisclosureSEC source: 0001093557-20-000071 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,749 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 22:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,386 | $151.46 | $361,383.56 |
DisclosureSEC source: 0001093557-19-000215 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,916 F1 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 244 | $159.92 | $39,020.75 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 11 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,302 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F13 · price: This transaction was executed in multiple trades at prices ranging from $159.37 to $160.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 269 | $158.42 | $42,614.68 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 10 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,546 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $158.25 to $159.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 450 | $157.78 | $70,998.84 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 9 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,815 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $157.25 to $158.24. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 550 | $156.43 | $86,038.98 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 8 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,265 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $156.12 to $156.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $155.36 | $15,535.50 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 7 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,815 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $155.00 to $155.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 40 | $154.00 | $6,159.90 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 6 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,915 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $153.85 to $154.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $152.59 | $91,554.06 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 5 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,955 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $152.13 to $152.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 621 | $151.49 | $94,076.53 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,555 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $151.1250 to $152.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 279 | $150.52 | $41,995.58 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,176 F4 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $150.09 to $150.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,629 | $150.11 | $844,975.38 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,455 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 325 | $145.43 | $47,263.52 |
DisclosureSEC source: 0001093557-19-000200 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,084 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.35 to $145.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 39,032 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,794 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 37 | $170.00 | $6,290.00 |
DisclosureSEC source: 0001093557-19-000191 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,409 F1 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,825 | $125.00 | $978,125.00 |
DisclosureSEC source: 0001093557-19-000155 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,392 F1 · shares: On February 28, 2019, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,296 | $142.79 | $327,850.89 |
DisclosureSEC source: 0001093557-19-000078 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,217 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,399 | $142.79 | $913,727.29 |
DisclosureSEC source: 0001093557-19-000078 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,513 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,222 | $142.79 | $317,284.27 |
DisclosureSEC source: 0001093557-19-000078 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,912 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:43 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000058 · wf-form4_155235137705765.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,134 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,373 | $121.38 | $530,782.50 |
DisclosureSEC source: 0001093557-18-000254 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.01 to $121.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 627 | $120.23 | $75,384.34 |
DisclosureSEC source: 0001093557-18-000254 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,478 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $120.00 to $120.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,498 | $144.43 | $216,358.54 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $144.23 to $144.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,502 | $143.88 | $216,100.55 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,603 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $143.10 to $144.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 800 | $142.13 | $113,704.00 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $142.00 to $142.53. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $141.25 | $169,500.96 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,905 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.00 to $141.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 21:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,009 | $125.24 | $251,597.72 |
DisclosureSEC source: 0001093557-18-000219 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.02 to $125.30. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 21:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,991 | $124.49 | $372,335.83 |
DisclosureSEC source: 0001093557-18-000219 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,114 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $124.00 to $124.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,400 | $145.27 | $639,174.36 |
DisclosureSEC source: 0001093557-18-000205 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $145.00 to $145.70. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $144.46 | $86,677.08 |
DisclosureSEC source: 0001093557-18-000205 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,505 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $144.00 to $144.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,180 | $143.76 | $457,141.54 |
DisclosureSEC source: 0001093557-18-000199 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,105 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,407 | $143.76 | $346,018.77 |
DisclosureSEC source: 0001093557-18-000199 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,285 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 22:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 550 | $124.96 | $68,727.01 |
DisclosureSEC source: 0001093557-18-000169 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,567 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $124.72 to $125.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 22:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,450 | $124.16 | $552,525.80 |
DisclosureSEC source: 0001093557-18-000169 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,117 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.65 to $124.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $100.73 | $50,365.00 |
DisclosureSEC source: 0001093557-18-000149 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,567 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,800 | $99.90 | $179,822.52 |
DisclosureSEC source: 0001093557-18-000149 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,067 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $99.65 to $100.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,700 | $99.12 | $267,628.05 |
DisclosureSEC source: 0001093557-18-000149 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,867 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $98.65 to $99.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:02 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,464 | $60.73 | $271,101.40 |
DisclosureSEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,567 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.